Juergen Thomale
Overview
Explore the profile of Juergen Thomale including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
615
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hansel C, Hlouschek J, Xiang K, Melnikova M, Thomale J, Helleday T, et al.
Cells
. 2021 Nov;
10(11).
PMID: 34831264
Tumor hypoxia and hypoxic adaptation of cancer cells represent major barriers to successful cancer treatment. We revealed that improved antioxidant capacity contributes to increased radioresistance of cancer cells with tolerance...
2.
Barr M, Gray S, Hoffmann A, Hilger R, Thomale J, OFlaherty J, et al.
PLoS One
. 2020 May;
15(5):e0233739.
PMID: 32437439
[This corrects the article DOI: 10.1371/journal.pone.0054193.].
3.
Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
Skowron M, Melnikova M, van Roermund J, Romano A, Albers P, Thomale J, et al.
Int J Mol Sci
. 2018 Feb;
19(2).
PMID: 29462944
Therapeutic efficacy of cisplatin-based treatment of late stage urothelial carcinoma (UC) is limited by chemoresistance. To elucidate underlying mechanisms and to develop new approaches for overcoming resistance, we generated long-term...
4.
Paul-Konietzko K, Thomale J, Arakawa H, Iliakis G
Photochem Photobiol
. 2015 Jul;
91(5):1173-80.
PMID: 26131740
In eukaryotic cells helix-distorting DNA lesions like cyclobutane pyrimidine dimers (CPDs) and 6-4 pyrimidine-pyrimidone photoproducts (6-4 PPs) are efficiently removed by nucleotide excision repair (NER). NER is a multistep process...
5.
Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, et al.
Int J Cancer
. 2014 Jun;
136(3):699-708.
PMID: 24895230
This phase I study tested the safety, feasibility, pharmacokinetics and pharmacodynamics of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion (HIPEC) in patients with platinum-sensitive recurrent epithelial ovarian cancer (EOC) undergoing...
6.
Barr M, Gray S, Hoffmann A, Hilger R, Thomale J, OFlaherty J, et al.
PLoS One
. 2013 Jan;
8(1):e54193.
PMID: 23349823
Introduction: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management of non-small cell lung cancer (NSCLC). Understanding the molecular mechanisms underlying this process may result...
7.
Galluzzi L, Vitale I, Senovilla L, Olaussen K, Pinna G, Eisenberg T, et al.
Cell Rep
. 2012 Aug;
2(2):257-69.
PMID: 22854025
Patients with non-small cell lung cancer (NSCLC) are routinely treated with cytotoxic agents such as cisplatin. Through a genome-wide siRNA-based screen, we identified vitamin B6 metabolism as a central regulator...
8.
Fenske A, Glaesener S, Bokemeyer C, Thomale J, Dahm-Daphi J, Honecker F, et al.
Cancer Lett
. 2012 May;
324(2):171-8.
PMID: 22613583
To identify factors involved in cisplatin (CDDP) resistance of germ cell tumours (GCTs), we exposed NTERA-2 cells, and the platinum-adapted subline NTERA-2R to CDDP and compared their response. While both...
9.
Yoon M, Bechmann L, Obermann M, Yepnjouo O, Egensperger R, Gerken G, et al.
Neurosci Bull
. 2010 Jul;
26(4):282-8.
PMID: 20657614
Objective: Cisplatin exerts its cytotoxic effect through distinct DNA lesions, leading to peripheral neuropathy. The risk of sensory neuropathy is a common problem during cancer treatment with cisplatin, leading to...
10.
Aleksunes L, Goedken M, Rockwell C, Thomale J, Manautou J, Klaassen C
J Pharmacol Exp Ther
. 2010 Jul;
335(1):2-12.
PMID: 20605904
The use of the chemotherapeutic drug cisplatin is limited in part by nephrotoxicity. Cisplatin causes renal DNA adducts and oxidative stress in rodents. The transcription factor Nrf2 (nuclear factor E2-related...